(-)-Epigallocatechin-3-gallate encapsulated realgar nanoparticles exhibit enhanced anticancer therapeutic efficacy against acute promyelocytic leukemia

doi:10.1080/10717544.2019.1672830

	(-)-Epigallocatechin-3-gallate encapsulated realgar nanoparticles exhibit enhanced anticancer therapeutic efficacy against acute promyelocytic leukemia
	Fang, Wei 3; Peng, Zhao Liang 4; Dai, Ya Ji 1; Wang, Dian Lei 2,3; Huang, Peng 3; Huang, He Ping 3
刊名	DRUG DELIVERY
	2019
卷号	26 期号:1 页码:1058-1067
关键词	EGCG-RNPs preparation characterization acute promyelocytic leukemia uptake efflux
ISSN号	1071-7544
DOI	10.1080/10717544.2019.1672830
通讯作者	Wang, Dian Lei(dlwang@ahtcm.edu.cn) ; Huang, Peng(great7701@126.com)
英文摘要	Realgar and (-)-Epigallocatechin-3-gallate (EGCG) are natural medicines that inhibit cancer cell growth, resulting in inhibition of formation and development of tumors. The anticancer effects of realgar and EGCG were greatly improved following formulation as nanoparticles. EGCG has received increased attention as a drug carrier. The aim of this study was to prepare a new nanomedicine, (EGCG-RNPs), in which encapsulated nano-realgar. EGCG-RNPs were prepared by coprecipitation and characterized by transmission electron microscopy (TEM), differential scanning calorimetry (DSC), particle size and zeta potential, X-ray diffraction, Fourier transform infrared spectroscopy (FTIR) and in vitro release. Furthermore, we evaluated the antiproliferative effects of EGCG-RNPs on HL-60 cells in vitro, antitumor effect by intratumoral injection of EGCG-RNPs into solid tumors derived from APL HL-60 cells in vivo. Possible mechanisms were evaluated using uptake and efflux experiments in HL-60 cells. The results showed that the average particle size and zeta potentials of EGCG-RNPs was 200.3 +/- 1.23 nm and -46.8 +/- 1.31 mV. Controlled release of EGCG-RNPs was sustained and continued up to 72 h in vitro. Compared with nano-realgar and EGCG + RNPs (EGCG and nano-realgar physical mixing), EGCG-RNPs significantly inhibited growth of HL-60 cells. In a solid tumor model, EGCG-RNPs decreased tumor volumes, with an inhibitory rate of 60.18% at a dose of 70 mg center dot kg(-1). The mechanisms of antitumor improvement may correlate with the increased uptake of realgar and prolonged the retention time of realgar in HL-60 cells due to EGCG as a carrier. EGCG-RNPs could enhance anticancer therapeutic efficacy for acute promyelocytic leukemia.
WOS关键词	ARSENIC TRIOXIDE ; POLYPHENOLS ; RELEASE
WOS研究方向	Pharmacology & Pharmacy
语种	英语
出版者	TAYLOR & FRANCIS LTD
WOS记录号	WOS:000507305700005
内容类型	期刊论文
源URL	[http://119.78.100.183/handle/2S10ELR8/282436]
专题	中国科学院上海药物研究所
通讯作者	Wang, Dian Lei; Huang, Peng
作者单位	1.Anhui Second Peoples Hosp, Hefei, Anhui, Peoples R China 2.Anhui Prov Key Lab Chinese Med Formula, Hefei, Anhui, Peoples R China 3.Anhui Univ Chinese Med, Coll Pharm, Qianjiang Rd 001, Hefei 230012, Anhui, Peoples R China 4.Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai, Peoples R China
推荐引用方式 GB/T 7714	Fang, Wei,Peng, Zhao Liang,Dai, Ya Ji,et al. (-)-Epigallocatechin-3-gallate encapsulated realgar nanoparticles exhibit enhanced anticancer therapeutic efficacy against acute promyelocytic leukemia[J]. DRUG DELIVERY,2019,26(1):1058-1067.
APA	Fang, Wei,Peng, Zhao Liang,Dai, Ya Ji,Wang, Dian Lei,Huang, Peng,&Huang, He Ping.(2019).(-)-Epigallocatechin-3-gallate encapsulated realgar nanoparticles exhibit enhanced anticancer therapeutic efficacy against acute promyelocytic leukemia.DRUG DELIVERY,26(1),1058-1067.
MLA	Fang, Wei,et al."(-)-Epigallocatechin-3-gallate encapsulated realgar nanoparticles exhibit enhanced anticancer therapeutic efficacy against acute promyelocytic leukemia".DRUG DELIVERY 26.1(2019):1058-1067.